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Ltd. This is an open access article unAbstract Photodynamic therapy has shown promise in the treatment of early head and neck
squamous cell carcinoma (SCC). In photodynamic therapy (PDT), a light sensitive drug (photo-
sensitizer) and visible light cause cancer cell death by the creation of singlet oxygen and free
radicals, inciting an immune response, and vascular collapse. In this paper, we review several
studies that demonstrate the effectiveness of PDT in the treatment of early stage SCC of the
head and neck, with some showing a similar response rate to surgery. Two cases are presented
to illustrate the effectiveness of PDT. Then, new advances are discussed including the discov-
ery of STAT3 crosslinking as a potential biomarker for PDT response and interstitial PDT for
locally advanced cancers.
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In photodynamic therapy (PDT), a light sensitive drug
(photosensitizer, PS), oxygen and visible light are required
to achieve a therapeutic response. To activate the PS, a
laser light is used to illuminate the treatment area. The
specific laser wavelength depends on the PS. Most clinically
approved PSs are activated with red light. PDT has 3 pri-
mary mechanisms of action: creation of singlet oxygen and
free radicals, inciting an immune response, and vascular
collapse.nd hosting by Elsevier B.V. on behalf of KeAi Communications Co.,
://creativecommons.org/licenses/by-nc-nd/4.0/).
Current state and future of photodynamic therapy 127Modern PDT came to the forefront with the work of
Dougherty et al in the 1970s at the Roswell Park Cancer
Institute.1 Their work led to the development of porforin
sodium (Photofrin), a hematoporphyrin derivative, and its
subsequent FDA approval. Porforin sodium is injected
intravenously, and requires 24e48 h to preferentially retain
in cancerous tissues. The other FDA approved photosensi-
tizer, 5-aminolevulinic acid (5-ALA, Levulan) is used topi-
cally and mainly for dermatologic conditions. The ALA is
absorbed through the skin or mucosa and is then converted
to the active drug within tissues. Temoporfin (mTHPC,
Foscan) is approved for use in Europe.
Multiple studies have demonstrated the effectiveness of
PDT in the treatment of early stage squamous cell carci-
noma (SCC) of the head and neck. In particular, it has been
shown to result in acceptable response when used to treat
T1/T2 SCCs of the oral cavity and glottic larynx.2e6 The
main advantages of PDT are that it can be safely repeated,
the PS itself has few minor side effects, does not preclude
further radiation or surgery, and heals with minimal scar-
ring. The main disadvantages are photosensitivity (up to 6
weeks), pain, and cost of the FDA approved drug.Fig. 1 Pre-PDT picture of a woman with a superficial T2N0
oral SCC.PDT for early stage SCC
PDT is ideally suited to superficial SCCs which can be easily
accessed by the treating surgeon. This has been investi-
gated most extensively in the oral cavity and larynx, where
PDT has been used to treat lesions ranging from dysplasia to
locally advanced squamous cell carcinoma. Rigual et al
demonstrated the efficacy of porfimer sodium for the
treatment of oral cavity squamous cell carcinoma in 2006,
and of HPPH in 2013.6,7 Complete response rates in the 23
patient cohort of T1 SCCA treated with HPPH reached 82%.
Durbec et al in 2013 examined the efficacy and safety of
PDT in recurrent carcinoma of the oral cavity and
oropharynx using Foscan, and observed a 93% complete
response rate.8 Jerjes observed a 5 year survival of 84.2%
and a recurrence rate of 15.8% in T1e2 SCCA of the oral
cavity treated with up to three rounds of mTHPC.9 Biel, in a
series of 113 oral cavity PDT patients, with 93.8% of pa-
tients with Cis-T2 tumors and 89.6% of patients with su-
perficial T2e3 tumors remaining free of disease after a
mean follow up of 90 months.3 A recent meta-analysis by
Cerrati et al found 24 studies comparing T1e2N0M0 squa-
mous cell carcinoma of the oral cavity to surgery.10 They
found no statistically significant difference between rates
of complete response to PDT, locoregional control with
surgery, or recurrence rate between the two modalities.
The similar response rates between surgery and PDT were
supported by the work of de Visscher et al, who compared
response rates, disease free survival and need for re-
treatment in superficial (<5 mm) T1e2 squamous cell car-
cinoma of the oral cavity.11 In tumors treated by PDT, an
86% complete response rate was observed in T1 lesions, and
a 63% complete response rate was observed for T2 lesions.
This was not significantly different than the control rates
observed in surgically treated T1 and T2 tumors, which
were 76% and 79%, respectively. Overall survival was similar
between the two treatment modalities when controlled for
stage.PDT treatment of laryngeal squamous cell carcinoma is
attractive because of the potential to preserve both voice
and swallowing integrity. Biel reported on 115 patients with
recurrent or primary laryngeal lesions, ranging from Cis to
T2N0 SCC, and observed a 5 year cure rate of 91%.2 All
recurrences were successfully salvaged by either PDT or
conventional means. A Phase Ib study carried out at Roswell
Park Cancer Institute examined response of laryngeal T1
squamous cell carcinoma of the larynx to HPPH treatment
as a secondary outcome, and observed an 82% complete
response rate.12
Case examples
Case 1 e oral SCC
A 65 year old woman presented with a T2 SCC of the mucosa
of the lower lip and vestibule. She had no significant past
medical history except for a 40 pack/yr smoking history.
The lesion was superficial, but extended onto the vestibule
and lower gingiva (Fig. 1). She was given the option of
surgery, radiation, or PDT and chose PDT. Two days before
the procedure she was injected with 2 mg/kg of porfimer
sodium. The procedure was done in the operating room
under general anesthesia. A laser was used to illuminate
the treatment area with a wavelength of 639 nm and a light
dose of 50 J/cm2 and 150 mW/cm.2 6 months later, she
remained disease free and had minimal scarring (Fig. 2).
Case 2 e T2 glottic SCC
A 63 year old man presented with a several month history of
hoarseness and dysphagia. Office examination revealed an
ulcerative left tonsil mass. Flexible laryngoscopy revealed a
lesion on the left false and true vocal cords (Fig. 3). Direct
laryngoscopy and biopsy showed a T2 SCC involving the left
false cord and extending to the true cord and anterior
commissure. He also had a concurrent T4N0 SCC of the left
tonsil. He chose to have a standard treatment for the tonsil
SCC (surgery and adjuvant treatment) and PDT for the
Fig. 2 Post-treatment (Fig. 1 patient), 6 months after PDT.
Fig. 3 Pre-PDT picture of a man with T2N0 laryngeal SCC.
128 C. Mimikos et al.larynx. Two days before the procedure he was injected with
2 mg/kg of porfimer sodium. He then underwent a sus-
pension laryngoscopy and was treated with surface illumi-
nation via a red laser at 630 nm wavelength, 100 J/cm2 andFig. 4 Post treatment (Fig. 3 patient), 2 months after PDT.150 mW/cm.2 Flexible laryngoscopy done 2 months post
procedure showed a complete response (Fig. 4). He has
shown no signs of recurrence after 2.5 years.
Recent advancements
A biomarker for quantifying PDT-induced
photoreaction
Recent work at our center has shown that STAT3 cross-
linking has the potential to predict the response to PDT.
The assay is done on a tissue biopsy collected from the
treatment area, immediately after PDT. In a recent study,
we found that a threshold of 10% STAT3 crosslinking is
associated with complete response in patients with T1N0
SCC of the oral cavity treated with HPPH-PDT.6 In patients
with carcinoma-in-situ and leukoplakia, we observed <10%
degree of STAT3 crosslinking, and this was associated with a
lower rate response (46% versus 82%) when compared to T1
SCC treated at the same PDT settings.
Pretreatment planning and real-time dosimetry
One of the drawbacks of conventional PDT is that is it
difficult to treat deep or thick lesions >1 cm in depth.
Interstitial PDT can circumvent this depth problem. For
patients who are unable to undergo further surgery or ra-
diation, this may be a viable option. Light fibers are placed
directly into the tumor either by direct visualization or by
image guidance (computerized tomography or ultrasound).
Several groups in Europe have demonstrated the benefits of
interstitial PDT with Foscan for the treatment of patients
with locally advanced head and neck SCC.13,14 Our group
has used interstitial PDT with Photofrin to treat these pa-
tients. Fig. 5 demonstrates one of our patients undergoing
interstitial PDT for a recurrent base of tongue SCC.
We have recently presented a new near real-time pre-
treatment planning algorithm to simulate the light propa-
gation in the tumor and adjacent structures during
treatment, which could help physicians to visualize the lightFig. 5 Patient with recurrent and locally advanced oropha-
ryngeal SCC, undergoing interstitial PDT.
Current state and future of photodynamic therapy 129dose distribution within tumors and adjacent tissues.15 In
this approach, for patients that are candidates for intersti-
tial PDT, a preoperative virtual 3D model of the tumor and
margins is created from a thin cut CT scan. This model is
used for pretreatment planning, to suggest fiber placement
and locations that will maximized light dose in the target
tumor while sparing adjacent healthy and sensitive tissues,
as we previously described in Oakley et al.15 In our institute,
treatment is done in the operating room with ultrasound
helping to guide fiber placement. During treatment, we use
our real-time light dosimetry system to monitor how much
light is being delivered to the tumor.
Summary
PDT can be an effective treatment for early stage SCCs of
the head and neck. The treatment is relatively easy to
perform, can be repeated, and has minimal scarring. With
new photosensitizers, the period of photosensitivity will be
reduced from weeks to days. Pre-treatment planning, real-
time dosimetry, and interstitial PDT have the potential to
help treat locally advanced head and neck SCCs.
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